Monash antibodies, Adelaide protein gels
Thursday, 22 January, 2009
Monash University has signed a deal with Danish pathology and cancer diagnostics specialist Dako to develop monoclonal antibodies for cancer research and treatment.
The Monash Antibody Technologies Facility (MATF), opened in September last year, will develop high-affinity antibodies for what it called “global commercialisation opportunities”.
MATF director Alan Sawyer said in a statement that the collaboration was part of the facility’s vision to provide the international research and diagnostics community with the best reagents possible.
Meanwhile, the Adelaide Proteomics Centre has decided to adopt publicly listed Fluorotechnics’ range of 2D gels and dyes for protein detection.
The centre has also agreed to become Fluorotechnics’ Australian reference customer and promote the company’s gels in Australia and internationally.
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
HRT linked to lower dementia risk in some women
Hormone replacement therapy may reduce the risk of dementia — particularly for certain...
